

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person <u>Parra Raul Jr.</u> (Last) (First) (Middle) <u>1600 WEST MERIT PARKWAY</u> (Street) <u>SOUTH JORDAN UT 84095</u> (City) (State) (Zip)			2. Issuer Name and Ticker or Trading Symbol <u>MERIT MEDICAL SYSTEMS INC [MMSI]</u>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) _____ CFO AND TREASURER		
			3. Date of Earliest Transaction (Month/Day/Year) <u>02/28/2023</u>			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person		
			4. If Amendment, Date of Original Filed (Month/Day/Year)					

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock, No Par Value	02/28/2023		A		10,183 ⁽¹⁾	A	\$0	16,871	D	
Common Stock, No Par Value	02/28/2023		F		3,174 ⁽²⁾	D	\$70.58	13,697	D	
Common Stock, No Par Value								2,872	I	By 401(k) Plan ⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Non-qualified stock options (right to buy)	\$70.58	02/28/2023		A		13,576		02/28/2024 ⁽⁴⁾	02/28/2030	Common Stock	13,576	\$0	13,576	D	
Non-qualified stock options (right to buy)	\$65.03							02/28/2023 ⁽⁵⁾	02/28/2029	Common Stock	14,570		14,570	D	
Non-qualified stock options (right to buy)	\$44.8							03/02/2019 ⁽⁶⁾	03/02/2025	Common Stock	4,000		4,000	D	
Non-qualified stock options (right to buy)	\$55.73							03/01/2020 ⁽⁷⁾	03/01/2026	Common Stock	30,000		30,000	D	
Non-qualified stock options (right to buy)	\$56.25							03/19/2022 ⁽⁸⁾	03/19/2028	Common Stock	9,681		9,681	D	
Non-qualified stock options (right to buy)	\$37.71							02/26/2021 ⁽⁹⁾	02/26/2027	Common Stock	16,722		16,722	D	

Explanation of Responses:

- These shares were acquired upon a determination of the Company's Compensation and Talent Development Committee that certain conditions had been met for the issuance of such shares pursuant to performance stock units that were granted on 02.26.2020 and 03.19.2021.
- These shares were not sold in an open-market transaction.

3. Represents plan holdings as of 01/31/2023.
4. Becomes exercisable in equal annual installments of 25% commencing 02/28/2024.
5. Becomes exercisable in equal annual installments of 25% commencing 02/28/2023.
6. Becomes exercisable in equal annual installments of 20% commencing 03/02/2019.
7. Becomes exercisable in equal annual installments of 20% commencing 03/01/2020.
8. Becomes exercisable in equal annual installments of 25% commencing 03/19/2022.
9. Becomes exercisable in equal annual installments of 25% commencing 02/26/2021.

/s/ Brian G. Lloyd, Attorney-in-Fact 03/02/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.